Considering epithelial cancers, the loss of E-cadherin expression is considered a prerequisite for tumor cell invasion and dedifferentiation [11,12,13,14] and it frequently parallels the de novo expression of mesenchymal cadherins, such as N-cadherin, a process called “cadherin switch”, which is a marker of the epithelial-to-mesenchymal transition (EMT) molecular process [15,16,17,18]. The gene discussed is CDH17; the disease is neoplasm.